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INTRODUCTION
The GABA A receptor complex is a Cl -channel that consists of multiple distinct subunits where drugs can act at specific binding sites to facilitate or inhibit GABA-mediated Cl -flux (referred to as positive and negative GABA A modulators, respectively; Mehta and Ticku, 1999) .
The consequences of positive and negative GABA A modulation are different, often resulting in opposite effects. For example, positive modulation can result in anxiolytic, anticonvulsant and respiratory depressant effects, whereas negative modulation can result in anxiogenic, convulsant and respiratory stimulant effects (Corda et al., 1983; Petersen, 1983; Wettstein et al., 1993) .
Some effects of negative modulators vary as a function of negative efficacy, e.g., increasing
negative efficacy results in increasing convulsant and anxiogenic-like effects (Corda et al., 1983; Petersen, 1983) . Thus, under some conditions, negative efficacy can be an important determinant of the effects of modulators acting at BZ sites.
Despite the many important therapeutic uses of BZs, one unwanted consequence of their use is dependence that emerges after repeated treatment, evidenced by a withdrawal syndrome that is characterized by anxiety, insomnia and, in some cases, tremor and convulsions (Woods et al., 1992) . Neutral modulators at BZ sites, like flumazenil, induce signs and symptoms of withdrawal in BZ-treated animals (Lukas and Griffiths, 1982; Griffiths et al., 1993) , thereby providing important drugs for evaluating BZ dependence. In addition to measuring directly observable signs and symptoms of withdrawal, there are other behavioral assays that can be used to examine BZ dependence. For example, sensitivity to the effects of flumazenil on rates of operant responding is enhanced during BZ treatment, perhaps due to the development of dependence (McMahon and France, 2002) . Moreover, sensitivity to the discriminative stimulus effects of flumazenil can be enhanced by BZ treatment, and the pharmacologic profile of the This article has not been copyedited and formatted. The final version may differ from this version.
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Whereas neutral modulators at BZ sites typically have little or no behavioral activity in untreated animals, negative modulators at BZ sites have anxiogenic-like and convulsant activity that increase as a function of efficacy (Corda et al., 1983; Petersen, 1983) ; thus, their use in vivo is somewhat limited. In contrast, both neutral and negative modulators at BZ sites can antagonize the behavioral effects of positive modulators at BZ sites and, furthermore, the behavioral effects of neutral and negative modulators can be strikingly similar in BZ-treated animals (Sannerud et al., 1991; Gerak and France, 1999; McMahon and France, 2005) . Thus, whereas the behavioral effects of BZ site ligands can be distinguished on the basis of negative efficacy in untreated animals, differences in negative efficacy appear less important for the behavioral effects of BZ site ligands in BZ-dependent animals. To test the hypothesis that the effects of BZ-site negative GABA A modulators do not vary as a function of efficacy in BZdependent animals, negative modulators that have low (Ro 15-4513) and high efficacy (β-CCE), as measured by inhibition of GABA A -mediated Cl -flux (Mehta and Ticku, 1989) , and that substitute for a flumazenil discriminative stimulus in diazepam (5.6 mg/kg/day)-treated monkeys , were studied in combination with positive modulators acting at different modulatory sites (BZ, barbiturate, and neuroactive steroid sites) on the GABA A receptor complex. Studies were conducted with pentobarbital and pregnanolone because a previous study in untreated monkeys indicated that negative modulators at BZ sites attenuate the effects of pregnanolone in an efficacy-dependent manner (i.e., negative efficacy appears to be positively correlated with antagonism of pregnanolone; McMahon and France, 2005 effect = slope * log(dose) + intercept. Straight lines were fitted to the linear portion of doseeffect curves, defined by doses producing 25-75% of the maximum effect, including not more than one dose producing less than 25% of the maximum effect, and not more than one dose producing more than 75% of the maximum effect. Other doses were excluded from the analyses.
The slopes of the three dose-effect curves generated from each drug combination were compared with an F-ratio test using GraphPad. If the slopes were not significantly different, then a common, best-fitting slope was used for further analyses (for detailed examples of this approach, see Kenakin, 1997) . For best-fitting models, doses corresponding to the 50% level of the effect (ED 50 ), potency ratios, and their 95% confidence limits (CL) were calculated by parallel line analyses (Tallarida, 2000) of data from individual subjects.
Control response rate represents the average of the five vehicle training sessions before the test. Response rate was calculated as a percentage of the control rate for individual animals, then averaged among subjects (± S.E.M.) and plotted as a function of dose.
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